Skip to Content
Joshua A.  Bauer

Joshua A. Bauer, Ph.D.

Research Assistant Professor of Biochemistry

Contact Information:

824 Robinson Research Building
2200 Pierce Avenue
Nashville, TN 37232


I currently lead the high-throughput screening team to facilitate the development and implementation of technologies to enable the discovery of chemical modulators of a variety of molecular targets and pathways in cancer cell biology. I also help develop pharmacological discoveries for anti-cancer agents and identify new lead compounds that benefit both mechanistic studies and drug discovery/development.  My research interests are focused on bioinformatic and chemical genomic approaches to identify novel cancer targets and to better understand the molecular and genetic mechanisms that underlie how cancer cells respond to therapeutics. A main goal is to identify novel strategies to overcome therapy resistance that will have clinical application.

  • B.S., University of Wisconsin- Madison
  • Ph.D., University of Michigan
  • Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290.
    Available from:
  • Xie J, Wang C, Virostko J, Manning HC, Pham W, Bauer J, Gore JC. A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. Chembiochem [print-electronic]. 2013 Aug 8/19/2013; 14(12): 1494-503. PMID: 23881799, PMCID: PMC3819221, DOI: 10.1002/cbic.201300142, ISSN: 1439-7633.
    Available from:
  • Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int [print-electronic]. 2013; 2013: 915636. PMID: 24303503, PMCID: PMC3835197, DOI: 10.1155/2013/915636, ISSN: 2314-6141.
    Available from:
  • Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform [print-electronic]. 2012; 11: 147-56. PMID: 22872785, PMCID: PMC3412597, PII: cin-11-2012-147, DOI: 10.4137/CIN.S9983, ISSN: 1176-9351.
    Available from:
  • Ye F, Bauer JA, Pietenpol JA, Shyr Y. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. BMC Genomics [print-electronic]. 2012; 13 Suppl 8: S3. PMID: 23281588, PMCID: PMC3535706, PII: 1471-2164-13-S8-S3, DOI: 10.1186/1471-2164-13-S8-S3, ISSN: 1471-2164.
    Available from:
  • Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011 Jul; 121(7): 2750-67. PMID: 21633166, PMCID: PMC3127435, PII: 45014, DOI: 10.1172/JCI45014, ISSN: 1558-8238.
    Available from:
  • Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res [print-electronic]. 2010 Jan 1/15/2010; 16(2): 681-90. PMID: 20068102, PMCID: PMC2892225, PII: 1078-0432.CCR-09-1091, DOI: 10.1158/1078-0432.CCR-09-1091, ISSN: 1078-0432.
    Available from:
  • Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res [print-electronic]. 2010; 12(3): R41. PMID: 20576088, PMCID: PMC2917036, PII: bcr2595, DOI: 10.1186/bcr2595, ISSN: 1465-542X.
    Available from: